Permacol™ collagen paste for cryptoglandular and Crohn's anal fistula.
Anal fistula
Anal sphincter
Collagen
Crohn’s disease
Fistula treatment
Minimally invasive surgical procedures
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
12
07
2018
accepted:
21
01
2019
pubmed:
14
2
2019
medline:
25
12
2019
entrez:
14
2
2019
Statut:
ppublish
Résumé
Permacol™ collagen paste, an acellular crosslinked porcine dermal collagen matrix suspension, is a new treatment option for anal fistula. Data remain limited, however, and as yet only the results of one case of Crohn's fistula treated with Permacol™ paste has been reported. The aim of this study was to assess the use of Permacol™ collagen paste in patients with cryptoglandular and Crohn's perianal fistulae. A prospective study was conducted on patients with anal fistula, treated with Permacol™ paste. Patients were followed at 1 week, 6 and 12 months, and on demand thereafter. The main focus was on fistula healing and postoperative continence. The former was defined as the absence of signs of recurrence on clinical examination, proctoscopy and rigid rectoscopy. Fecal incontinence was assessed before surgery and at each follow-up. Thirty patients (19 women, 11 men; mean age 46 years), 12 (40%) of whom had Crohn's disease were included. The average number of previous fistula operations was 6. All patients had ≥ 6 months of follow-up, and 24 patients (80%) had ≥ 12 months of follow-up. The healing rate in all patients was 57% (17 of 30 patients) at 6 months and 63% (15 of 24 patients) at 12 months. One patient reported a worsening of fecal incontinence at 12 months; 2 patients had adverse events (perianal pain: n = 1, fluid accumulation n = 1) requiring fistula drainage. Patient characteristics, healing, incontinence, and adverse events did not differ significantly between patients with and without Crohn's disease. Our data indicate that Permacol™ paste is a safe and moderately effective treatment for cryptoglandular and Crohn's fistulae.
Sections du résumé
BACKGROUND
BACKGROUND
Permacol™ collagen paste, an acellular crosslinked porcine dermal collagen matrix suspension, is a new treatment option for anal fistula. Data remain limited, however, and as yet only the results of one case of Crohn's fistula treated with Permacol™ paste has been reported. The aim of this study was to assess the use of Permacol™ collagen paste in patients with cryptoglandular and Crohn's perianal fistulae.
METHODS
METHODS
A prospective study was conducted on patients with anal fistula, treated with Permacol™ paste. Patients were followed at 1 week, 6 and 12 months, and on demand thereafter. The main focus was on fistula healing and postoperative continence. The former was defined as the absence of signs of recurrence on clinical examination, proctoscopy and rigid rectoscopy. Fecal incontinence was assessed before surgery and at each follow-up.
RESULTS
RESULTS
Thirty patients (19 women, 11 men; mean age 46 years), 12 (40%) of whom had Crohn's disease were included. The average number of previous fistula operations was 6. All patients had ≥ 6 months of follow-up, and 24 patients (80%) had ≥ 12 months of follow-up. The healing rate in all patients was 57% (17 of 30 patients) at 6 months and 63% (15 of 24 patients) at 12 months. One patient reported a worsening of fecal incontinence at 12 months; 2 patients had adverse events (perianal pain: n = 1, fluid accumulation n = 1) requiring fistula drainage. Patient characteristics, healing, incontinence, and adverse events did not differ significantly between patients with and without Crohn's disease.
CONCLUSIONS
CONCLUSIONS
Our data indicate that Permacol™ paste is a safe and moderately effective treatment for cryptoglandular and Crohn's fistulae.
Identifiants
pubmed: 30758690
doi: 10.1007/s10151-019-01932-z
pii: 10.1007/s10151-019-01932-z
doi:
Substances chimiques
Ointments
0
Permacol
0
Collagen
9007-34-5
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-141Références
World J Gastroenterol. 2009 Sep 14;15(34):4263-72
pubmed: 19750568
Clin Colon Rectal Surg. 2007 Nov;20(4):282-93
pubmed: 20011424
Dis Colon Rectum. 2011 Oct;54(10):1279-83
pubmed: 21904143
Tech Coloproctol. 2011 Dec;15(4):417-22
pubmed: 22002535
Colorectal Dis. 2012 Dec;14 Suppl 3:24-8
pubmed: 23136821
Colorectal Dis. 2014 Feb;16(2):110-5
pubmed: 24119103
Surg Innov. 2014 Oct;21(5):476-80
pubmed: 24201738
World J Gastroenterol. 2014 Oct 7;20(37):13205-10
pubmed: 25309057
World J Gastroenterol. 2015 Feb 7;21(5):1394-403
pubmed: 25663759
Tech Coloproctol. 2015 Aug;19(8):449-53
pubmed: 25724967
Tech Coloproctol. 2016 Nov;20(11):753-758
pubmed: 27669711
Tech Coloproctol. 2017 Mar;21(3):211-215
pubmed: 28210857
Colorectal Dis. 2017 May 11;:null
pubmed: 28493393
Surg Endosc. 2018 Apr;32(4):2084-2093
pubmed: 29052068
Gut. 2018 Jun;67(6):1181-1194
pubmed: 29331943
Adv Ther. 2018 Aug;35(8):1232-1238
pubmed: 29968009
Surg Innov. 2019 Apr;26(2):168-179
pubmed: 30339103
Gastroenterol Hepatol (N Y). 2018 Sep;14(9):521-528
pubmed: 30364296
Dis Colon Rectum. 1994 Dec;37(12):1194-7
pubmed: 7995143